On the scale that NRU and the MAPLE projects were envisaged in terms of medical isotope reactors, I'm not aware of any new initiatives.
If you look at this supply chain, all the major large-producing reactors in the world are actually owned by governments, and generally the supply chain is a combination of private-public partnerships, and governments and taxpayers have invested in infrastructure to build these reactors to supply large quantities. I am making a differentiation between large and much smaller quantities that perhaps would serve a very local requirement. Here we're talking about our particular situation, where we supply more than 50% of the isotopes around the world. Those reactors are owned by governments, not by private companies. Companies like Nordion have invested a lot of money in the supply chain, and we are the processors. That's the role we play: the reactors supply the isotopes, the processors are perhaps the customers of the reactors, then we purify and distribute the isotopes to our customers.
That is the framework. Just to reassert and answer your question, I am not aware of any private enterprise initiatives today on the scale we see in terms of a MAPLE or an NRU or any of the other larger reactors around the world.